The p53 pathway in breast cancer

Milena Gasco(Universidad Complutense de Madrid), Tim Crook(Bupa Cromwell Hospital)
Breast Cancer Research
April 1, 2002
10.1186/bcr426
Cited by 396

Related Papers

Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma
|Cell Death and Disease|2013|169
Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer
|Cancer Research|2011|60
DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt's lymphoma
|British Journal of Cancer|2010|34
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in cancer
|Oncotarget|2012|33
Supplementary Figure 3 from Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer
|Unknown|2023|0